Avandia Lawsuit News

07/03/2008
Clinical trial designs for diabetes drugs are not good enough at detecting cardiovascular risk with GlaxoSmithKline’s (GSK) Avandia being Exhibit A, according to experts at a Tuesday meeting of CDER’s Endocrinologic and Metabolic Drugs Advisory Committee.

07/01/2008
Drugs designed to control type 2 diabetes should be subjected to more thorough safety reviews to ensure they don't raise the risk of heart problems, U.S. Food and Drug Administration advisers said Wednesday.

06/25/2008
Sam P. is happy to no longer be taking Avandia. He says he suffered severe side effects shortly after starting the medication, although he did not realize Avandia could have been causing his health problems.

06/13/2008
Otis is a coach and teacher at a high school in Texas. He was put on Avandia for his diabetes approximately five years ago. In the fall of 2006 he was hospitalized for a heart attack.

More Avandia News:::

Avandia Side Effects Lawsuit
NO RECOVERY... NO FEES...NO COSTS

Avandia - Rosiglitazone is a widely prescribed medication to treat Type-2 Diabetes Mellitus, a condition which also known as Adult-Onset Diabetes. Manufactured by GlaxoSmithKline, Avandia (Rosiglitazone) was approved for the treatment of Type-2 Diabetes in the U.S. in 1999. Avandia is also contained in combination with other drugs in medications called Avandryl and Avandamet. To date, more than six (6) million people worldwide have taken the drug, and Avandia generates approximately $3.2 billion in annual sales for its manufacturer. However, on May 21, 2007, the United States Food & Drug Administration ("FDA") issued a Safety Alert regarding Avandia. To date there has not yet been a recall or a black box warning required by the FDA for Avandia.

The FDA Safety Alert warns that patients who are taking Avandia (rosiglitazone) - especially those who are known to have underlying heart disease or who are at high risk of heart attack (myocardial infarction) -  should speak to their physicians about their continued use of Avandia.

The FDA's Safety Alert follows a study released on the same day, which will appear in the June 14, 2007 issue of the New England Journal of Medicine. This type of study, known as a 'meta-analysis', evaluated forty-two (42) separate studies comparing patients using Avandia (rosiglitazone) to patients who were not using Avandia. This study concludes that patients taking Avandia (rosiglitazone) face a 43% increased risk of heart attack, and a 64% increased risk of dying from heart related ( cardiovascular) disease. Cardiovascular disease refers to the class of diseases that affect the heart and/or blood vessels, which includes but is not limited to heart attacks (myocardial infarction), strokes, aneurysms, congestive heart failure, and arrhythmia. As indicated above, there has not yet been a recall, nor has the FDA yet required that the manufacturer issue a black box warning label for Avandia, but in the event Avandia is subjected to a recall, this site will be updated.

ALERT - On June 7, 2007 the FDA ordered an Avandia Black Box Warning.

If you or a loved one have experienced an Avandia heart attack, or Avandia stroke, Avandia congestive heart failure, Avandia cardiovascular disease or if you have lost a loved one to an Avandia death you may be entitled to compensation. Contact the Avandia lawyers of Ennis & Ennis, P.A. today about an Avandia lawsuit. Call us toll free for a free, confidential case evaluation or fill out our online Avandia case evaluation form on this page.